Published in J Histochem Cytochem on November 01, 1982
Distribution of urokinase-type plasminogen activator immunoreactivity in the mouse. J Cell Biol (1984) 1.40
Immunocytochemical localization of urokinase-type plasminogen activator in Lewis lung carcinoma. J Cell Biol (1984) 1.13
Monoclonal antibodies to human urokinase identify the single-chain pro-urokinase precursor. Proc Natl Acad Sci U S A (1984) 1.10
Up-regulation of urokinase and urokinase receptor genes in malignant astrocytoma. Am J Pathol (1995) 1.03
Monoclonal antibody to human 66,000 molecular weight plasminogen activator from melanoma cells. Specific enzyme inhibition and one-step affinity purification. EMBO J (1983) 0.99
Prognostic role of urokinase-type plasminogen activator in human gliomas. Am J Pathol (1995) 0.91
Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res (1985) 8.64
HL-A antigens and diabetes mellitus. Lancet (1974) 4.42
HL-A antigens and disease. Statistical and genetical considerations. Tissue Antigens (1974) 4.41
Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis. EMBO J (1990) 3.27
Suggestion of linkage of a major locus for nonsyndromic orofacial cleft with F13A and tentative assignment to chromosome 6. Clin Genet (1987) 3.14
Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma. Cancer Res (1997) 2.98
Linkage relationships of paraoxonase (PON) with other markers: indication of PON-cystic fibrosis synteny. Clin Genet (1985) 2.96
Two distinct phases of apoptosis in mammary gland involution: proteinase-independent and -dependent pathways. Development (1996) 2.88
HL-A and disease associations--a survey. Transplant Rev (1975) 2.87
Oral epithelial dysplasia classification systems: predictive value, utility, weaknesses and scope for improvement. J Oral Pathol Med (2008) 2.82
Cellular receptor for urokinase plasminogen activator. Carboxyl-terminal processing and membrane anchoring by glycosyl-phosphatidylinositol. J Biol Chem (1991) 2.68
Urokinase-type plasminogen activator: proenzyme, receptor, and inhibitors. J Cell Biol (1987) 2.63
Plasminogen activation by receptor-bound urokinase. A kinetic study with both cell-associated and isolated receptor. J Biol Chem (1991) 2.61
Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. Am J Pathol (1991) 2.38
Nonsense suppressors of Saccharomyces cerevisiae can be generated by mutation of the tyrosine tRNA anticodon. Nature (1976) 2.07
Biosynthesis of the beta and beta' subunits of RNA polymerase in Escherichia coli. J Mol Biol (1973) 2.03
Transforming growth factor-beta is a strong and fast acting positive regulator of the level of type-1 plasminogen activator inhibitor mRNA in WI-38 human lung fibroblasts. EMBO J (1987) 1.98
Ultrastructural localization of plasma membrane-associated urokinase-type plasminogen activator at focal contacts. J Cell Biol (1988) 1.97
Properties of the K562 cell line, derived from a patient with chronic myeloid leukemia. Int J Cancer (1976) 1.97
MLC typing in juvenile diabetes mellitus and idiopathic Addison's disease. Transplant Rev (1975) 1.97
Cancer invasion and tissue remodeling: common themes in proteolytic matrix degradation. Curr Opin Cell Biol (1998) 1.95
Tissue distribution of histo-blood group antigens. APMIS (2000) 1.94
Activation of pro-urokinase and plasminogen on human sarcoma cells: a proteolytic system with surface-bound reactants. J Cell Biol (1989) 1.93
Laminin-5 is a marker of invading cancer cells in some human carcinomas and is coexpressed with the receptor for urokinase plasminogen activator in budding cancer cells in colon adenocarcinomas. Cancer Res (1995) 1.93
Replication of the F'lac sex factor in the cell cycle of Escherichia coli. Mol Gen Genet (1971) 1.92
High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res (1993) 1.86
Purification of zymogen to plasminogen activator from human glioblastoma cells by affinity chromatography with monoclonal antibody. Biochemistry (1982) 1.85
The gamma 2 chain of kalinin/laminin 5 is preferentially expressed in invading malignant cells in human cancers. Am J Pathol (1994) 1.79
Distinct localizations of urokinase-type plasminogen activator and its type 1 inhibitor under cultured human fibroblasts and sarcoma cells. J Cell Biol (1987) 1.79
Messenger RNA for two type IV collagenases is located in stromal cells in human colon cancer. Am J Pathol (1993) 1.71
Localization of messenger RNA for Mr 72,000 and 92,000 type IV collagenases in human skin cancers by in situ hybridization. Cancer Res (1992) 1.71
Functional overlap between two classes of matrix-degrading proteases in wound healing. EMBO J (1999) 1.69
Plasminogen activator inhibitor type-1: reactive center and amino-terminal heterogeneity determined by protein and cDNA sequencing. FEBS Lett (1986) 1.68
New malignancy grading is a better prognostic indicator than Broders' grading in oral squamous cell carcinomas. J Oral Pathol Med (1989) 1.65
Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis. J Natl Cancer Inst (1999) 1.64
Somatic mutation of the Peutz-Jeghers syndrome gene, LKB1/STK11, in malignant melanoma. Oncogene (1999) 1.59
Observer variability in the histologic assessment of oral premalignant lesions. J Oral Pathol Med (1995) 1.58
The p16-cyclin D/Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis. Cancer Res (1996) 1.55
Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. Cancer Res (1994) 1.55
Urokinase plasminogen activator cleaves its cell surface receptor releasing the ligand-binding domain. J Biol Chem (1992) 1.55
Hybridization of a myeloid leukemia-derived human cell line (K562) with a human Burkitt's lymphoma line (P3HR-1). J Natl Cancer Inst (1980) 1.53
The ligand-binding domain of the cell surface receptor for urokinase-type plasminogen activator. J Biol Chem (1991) 1.52
Biosynthesis of intestinal microvillar proteins. Characterization of intestinal explants in organ culture and evidence for the existence of pro-forms of the microvillar enzymes. Biochem J (1982) 1.52
Inhibition of receptor-bound urokinase by plasminogen-activator inhibitors. J Biol Chem (1990) 1.52
Plasminogen activator inhibitor from human fibrosarcoma cells binds urokinase-type plasminogen activator, but not its proenzyme. J Biol Chem (1986) 1.51
Reduced metastasis of Polyoma virus middle T antigen-induced mammary cancer in plasminogen-deficient mice. Oncogene (1998) 1.51
Localization of urokinase-type plasminogen activator in stromal cells in adenocarcinomas of the colon in humans. Am J Pathol (1991) 1.50
A 55,000-60,000 Mr receptor protein for urokinase-type plasminogen activator. Identification in human tumor cell lines and partial purification. J Biol Chem (1988) 1.49
Molecular species of plasminogen activators secreted by normal and neoplastic human cells. Cancer Res (1980) 1.49
Lactational competence and involution of the mouse mammary gland require plasminogen. Development (2000) 1.48
Constitutive activation of a slowly migrating isoform of Stat3 in mycosis fungoides: tyrphostin AG490 inhibits Stat3 activation and growth of mycosis fungoides tumor cell lines. Proc Natl Acad Sci U S A (1997) 1.47
Inhibition of constitutively activated Stat3 correlates with altered Bcl-2/Bax expression and induction of apoptosis in mycosis fungoides tumor cells. Leukemia (1999) 1.45
The receptor for urokinase-type plasminogen activator is not essential for mouse development or fertility. J Biol Chem (1995) 1.45
The HL-A7 histocompatibility antigen in sarcoidosis in relation to tuberculin sensitivity. Tissue Antigens (1975) 1.45
A urokinase receptor-associated protein with specific collagen binding properties. J Biol Chem (2000) 1.44
The human receptor for urokinase plasminogen activator. NH2-terminal amino acid sequence and glycosylation variants. J Biol Chem (1990) 1.43
Inducibility of the Epstein-Barr virus (EBV) cycle and surface marker properties of EBV-negative lymphoma lines and their in vitro EBV-converted sublines. Int J Cancer (1976) 1.41
Somatic Fas mutations in non-Hodgkin's lymphoma: association with extranodal disease and autoimmunity. Blood (1998) 1.41
Regulation of urokinase receptors in monocytelike U937 cells by phorbol ester phorbol myristate acetate. J Cell Biol (1989) 1.41
Endotoxin-stimulated human monocyte secretion of interleukin 1, tumour necrosis factor alpha, and prostaglandin E2 shows stable interindividual differences. Scand J Immunol (1988) 1.40
Constitutive STAT3-activation in Sezary syndrome: tyrphostin AG490 inhibits STAT3-activation, interleukin-2 receptor expression and growth of leukemic Sezary cells. Leukemia (2001) 1.40
Distribution of urokinase-type plasminogen activator immunoreactivity in the mouse. J Cell Biol (1984) 1.40
Collagenase-3 expression in breast myofibroblasts as a molecular marker of transition of ductal carcinoma in situ lesions to invasive ductal carcinomas. Cancer Res (2001) 1.40
Peptide-derived antagonists of the urokinase receptor. affinity maturation by combinatorial chemistry, identification of functional epitopes, and inhibitory effect on cancer cell intravasation. Biochemistry (2001) 1.40
Higher-order structure of human mitotic chromosomes. Proc Natl Acad Sci U S A (1977) 1.38
Isolation of novel HLA-DR restricted potential tumor-associated antigens from the melanoma cell line FM3. Cancer Res (1997) 1.38
The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients. Cancer Res (1998) 1.38
Expression of polypeptide GalNAc-transferases in stratified epithelia and squamous cell carcinomas: immunohistological evaluation using monoclonal antibodies to three members of the GalNAc-transferase family. Glycobiology (1999) 1.37
One-chain urokinase-type plasminogen activator from human sarcoma cells is a proenzyme with little or no intrinsic activity. J Biol Chem (1988) 1.33
Cell-induced potentiation of the plasminogen activation system is abolished by a monoclonal antibody that recognizes the NH2-terminal domain of the urokinase receptor. FEBS Lett (1991) 1.32
Urokinase- and tissue-type plasminogen activators in keratinocytes during wound reepithelialization in vivo. J Invest Dermatol (1988) 1.32
Identification of an Epstein-Barr virus-coded thymidine kinase. EMBO J (1986) 1.31
Cellular glycosylphosphatidylinositol-specific phospholipase D regulates urokinase receptor shedding and cell surface expression. J Cell Physiol (1999) 1.30
92 kDa type IV collagenase (MMP-9) is expressed in neutrophils and macrophages but not in malignant epithelial cells in human colon cancer. Int J Cancer (1996) 1.30
Accessibility of receptor-bound urokinase to type-1 plasminogen activator inhibitor. Proc Natl Acad Sci U S A (1989) 1.29
Internalization of the urokinase-plasminogen activator inhibitor type-1 complex is mediated by the urokinase receptor. J Biol Chem (1992) 1.29
Immunohistochemical localization of urokinase- and tissue-type plasminogen activators in psoriatic skin. J Invest Dermatol (1987) 1.28
Urokinase and plasminogen activator inhibitor type 1 in pulmonary adenocarcinoma. Cancer Res (1994) 1.28
A precise and efficient stereological method for determining murine lung metastasis volumes. Am J Pathol (2001) 1.28
Alterations of the MMAC1/PTEN gene in lymphoid malignancies. Blood (1998) 1.27
STAT3-mediated constitutive expression of SOCS-3 in cutaneous T-cell lymphoma. Blood (2001) 1.27
ELISA determination of soluble urokinase receptor in blood from healthy donors and cancer patients. Clin Chem (1997) 1.26
Accumulation of identical T cells in melanoma and vitiligo-like leukoderma. J Invest Dermatol (1999) 1.24
Differential expression of urokinase-type plasminogen activator and its type-1 inhibitor during healing of mouse skin wounds. J Invest Dermatol (1991) 1.23